Myocardial remodeling, an overview

Heart Failure Reviews

Volumn 16, Issue 1, 2011, Pages 1-4

  Cokkinos, Dennis V ^b   Pantos, Costas ^a  

^a UNIVERSITY OF ATHENS   (Greece)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ALISKIREN; ALPHA ACTIN; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLENBUTEROL; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN; ESTRADIOL; ETANERCEPT; EXENDIN 4; GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INFLIXIMAB; MATRIX METALLOPROTEINASE; METFORMIN; PHOSPHOLAMBAN; QUERCETIN; RANOLAZINE; RAPAMYCIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RESVERATROL; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE; SILDENAFIL; STAT3 PROTEIN; TESTOSTERONE; TETRACYCLINE; THYROID HORMONE; VALPROIC ACID;

ANGIOPLASTY; AORTA VALVE REGURGITATION; CAPILLARY DENSITY; CARDIOMEGALY; CARDIOMYOPATHY; CARDIOVASCULAR FUNCTION; DEATH; ENERGY CONSUMPTION; ENZYME ACTIVITY; EXTRACELLULAR MATRIX; GENE OVEREXPRESSION; GENOMICS; HEART DILATATION; HEART DISEASE; HEART FAILURE; HEART INFARCTION; HEART MUSCLE CONTRACTILITY; HEART MUSCLE REPERFUSION; HYPERTENSION; MOLECULAR DYNAMICS; MYOCARDIAL REMODELING; NONHUMAN; OXYGENATION; PROTEOMICS; REPERFUSION INJURY; REVIEW; TRANSGENE;

FIBROSIS; HEART FAILURE; HUMANS; MYOCARDIUM; VENTRICULAR REMODELING;

EID: 78650976567     PISSN: 13824147     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10741-010-9192-4     Document Type: Review

References (29)

1. J Diez GA Ertl 2009 Translational approach to myocardial remodelling Cardiovasc Res 81 409 411 1:CAS:528:DC%2BD1MXhtlKitL4%3D 10.1093/cvr/cvn352 19095718
2. JA Hill EN Olson 2008 Cardiac plasticity N Engl J Med 358 1370 1380 1:CAS:528:DC%2BD1cXjvFOnsb8%3D 10.1056/NEJMra072139 18367740 (Pubitemid 351468414)
3. C Savoye O Equine O Tricot, et al. 2006 Left ventricular remodelling after anterior wall acute myocardial infarction in modern clinical practice (from the Remodelage Ventriculaire [REVE] study group Am J Cardiol 98 1144 1149 10.1016/j.amjcard.2006.06.011 17056315 (Pubitemid 44584097)
4. CE Papadopoulos HI Karvounis G Giannakoulas, et al. 2007 Predictors of left ventricular remodelling after reperfused acute myocardial infarction Am J Cardiol 99 1024 1025 10.1016/j.amjcard.2006.11.028 17398206 (Pubitemid 46483270)
5. T Miura T Miki 2008 Limitation of myocardial infarct size in the clinical setting: current status and challenges in translating animal experiments into clinical therapy Basic Res Cardiol 103 501 513 10.1007/s00395-008-0743-y 18716709
6. C Tribouilloy G Grigioni J-F Avierinos, et al. 2009 Survival implications of left ventricular end-systolic diameter in mitral regurgitation due to flail leaflets: a long-term follow-up multicenter study J Am Coll Cardiol 54 1961 1968 10.1016/j.jacc.2009.06.047 19909877
7. ETH Yeh Cl Bickford 2009 Cardiovascular complications of cancer therapy J Am Coll 53 2231 2247 1:CAS:528:DC%2BD1MXoslajsrg%3D 10.1016/j.jacc.2009.02.050
8. JM Pfeffer MA Pfeffer E Braunwald 1985 Influence on chronic captopril theraphy on the infarcted left ventricle of the rat Circ Res 57 84 95 1:CAS:528:DyaL2MXltlCktLg%3D 3891127
9. LH Opie RJ Commerford BJ Gersh, et al. 2006 Controversies in ventricular remodeling Lancet 367 356 367 10.1016/S0140-6736(06)68074-4 16443044 (Pubitemid 43151469)
10. GW Dorn II J Robbins PH Sugden 2003 Phenotyping hypertrophy: eschew obfuscation Circ Res 92 171 1175 10.1161/01.RES.0000077012.11088.BC (Pubitemid 36723642)
11. M Burak NG Frangogiannis 2007 The role of TGF-β signaling in myocardial infarction and cardiac remodeling Cardiovasc Res 74 184 195 10.1016/j.cardiores.2006.10.002 (Pubitemid 46517504)
12. N Frey EN Olson 2003 Cardiac hypertrophy: the good, the bad and the ugly Annu Rev Physiol 65 45 79 1:CAS:528:DC%2BD3sXjt1Glt74%3D 10.1146/annurev. physiol.65.092101.142243 12524460 (Pubitemid 38249147)
13. BD Westenbrink W-PT Ruifrok AA Voors, et al. 2010 Vascular endothelial growth factor is crucial for erythropoietin-induced improvement of cardiac function in heart failure Cardiovasc Res 87 30 39 1:CAS:528:DC%2BC3cXnsVOmu7k%3D 10.1093/cvr/cvq041 20139114
14. B Swynghedaw 2006 Phenotypic plasticity of adult myocardium. Molecular mechanisms J Exp Biol 209 2320 2327 10.1242/jeb.02084 (Pubitemid 44065526)
15. M Rajabi C Kassiotis P Razeghi H Taegtmeyer 2007 Return to the fetal gene program protects the stressed heart: a strong hypothesis Heart Fail Rev 12 331 343 1:CAS:528:DC%2BD2sXnvFKnt7o%3D 10.1007/s10741-007-9034-1 17516164 (Pubitemid 350176706)
16. G Heusch R Schulz SH Rahimtoola 2005 Myocardial hibernation-a delicate balance Am J Physiol Heart Circ Physiol 288 H984 H999 1:CAS:528: DC%2BD2MXisVKqtLY%3D 10.1152/ajpheart.01109.2004 15563526 (Pubitemid 40269997)
17. JE Baker P Holman GJ Gross 1999 Preconditioning in immature rabbit hearts: role of Katp channels Circulation 99 1249 1254 1:CAS:528: DyaK1MXitVelsLs%3D 10069795
18. M Krenz J Robbins 2004 Impact of beta-myosin heavy chain expression on cardiac function during stress J Am Coll Cardiol 44 2390 2397 1:CAS:528:DC%2BD2cXhtVyqs7%2FO 10.1016/j.jacc.2004.09.044 15607403 (Pubitemid 39647615)
19. C Cleniewski-Bernard P Mulder JP Henry, et al. 2008 Proteomic analysis of left ventricular remodeling in an experimental model of heart failure J Proteome Res 7 5004 5016 10.1021/pr800409u
20. R Sarwar SA Copok 2009 Genomic analysis of left ventricular remodelling Circulation 120 437 444 10.1161/CIRCULATIONAHA.108.797225 19652118
21. AJ Tijsen EE Creemers PD Moerland, et al. 2010 MiR423-5p as a circulating biomarker for heart failure: questions about MiR-423-5p Circ Res 106 1035 1039 1:CAS:528:DC%2BC3cXksVaqsLc%3D 10.1161/CIRCRESAHA.110.218297 20185794
22. SJ Matkovich W Wang Y Tu, et al. 2010 MicroRNA-133a protects against myocardial fibrosis and modulates electrical repolarization without affecting hypertrophy in pressure-overload adult hearts Circ 106 166 175 1:CAS:528:DC%2BD1MXhs1aqt7bN 10.1161/CIRCRESAHA.109.202176
23. RA De Boer AA Voors P Muntendam, et al. 2009 Galectin-3: a novel mediator of heart failure development progression Eur J Heart Fail 11 811 817 10.1093/eurjhf/hfp097 19648160
24. RAP Weir AM Miller GEJ Murphy, et al. 2010 Soluble ST2 is marker for predicting post-MI recovery J Am Coll 55 243 250 1:CAS:528:DC%2BC3cXitlagtrg%3D 10.1016/j.jacc.2009.08.047
25. KG Shyu MJ Lu BM Wang, et al. 2006 Myostatin expression in ventricular myocardium in rat model of volume-overload heart failure Eur J Clin Invest 36 713 719 1:CAS:528:DC%2BD28XhtFChtLjN 10.1111/j.1365-2362.2006.01718.x 16968467 (Pubitemid 44393930)
26. I George LT Bish G Kamalakkannan, et al. 2010 Myostatin activation in patients with advanced heart failure and after mechanical unloading Eur J Heart Fail 12 420 422 10.1093/eurjhf/hfq039
27. H Ishii T Amano T Matsubara T Myrohara, et al. 2008 Pharmacological intervention for prevention of left ventricular remodeling and improving prognosis in myocardial infarction Circulation 118 2710 2718 10.1161/CIRCULATIONAHA.107.748772 19106394
28. L Bolognese AN Nescovic G Parodi, et al. 2002 Left ventricular remodeling after primary coronary angioplasty: patterns of left ventricular dilation and long-term prognostic implications Circulation 106 2351 2357 10.1161/01.CIR. 0000036014.90197.FA 12403666 (Pubitemid 35244737)
29. DV Cokkinos 2004 Preconditioning-a paradigm of yin and yang Hellenic J Cardiol 43 179 182